PATENT CLAIM ANALYSIS

Application Number: 16404165
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-10
Patent Classification: ["424", "093210"]

Abstract:
An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

Claim (Index 26):
An anticancer agent comprising the isolated T cell or a culture comprising the isolated T cell according to  claim 25  and a pharmaceutically acceptable additive.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 100.0
- Lexical Diversity: 2.47368
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15513870', '14211784', '15897743', '15550645', '14991145']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7481381245833163
- 35 USC 102 Novelty (BERT): 0.6404478158544871
- Combined Prediction Score: 0.7373690937104334
- Mean Citation Score: 434.63642800000014
- Max Citation Score: 773.3037
- Similarity Product: 547.4191907219232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test